About the potential partner
The company was established in 1991, and it is a high-tech enterprise integrating production, research and development, and marketing of in vitro diagnostic reagents and genetic engineered vaccines. The company mainly produces the whole set reagents for serum screening of HBsAg, HCV, HIV, TP, TRUST, enzyme linked immunosorbent agents and gold colloid quick test agents for hepatitis, venereal disease and tumors. At present,the company has developed into the largest manufacturer of immune diagnostic reagents in China and Asia, with an annual output of 200 million portions. Its blood screening diagnostics market share ranks first in the country, and output of immune diagnostic agents for AIDS and hepatitis C has occupied the first place for many years continuously.

Cooperation demand description:
High-quality in vitro diagnostic reagents need critical materials including high-quality antigen or antibodies. As the business continues to develop, the company needs to continually develop new diagnostic reagents, and the company has established projects for in vitro diagnostic agents on respiratory diseases, tumor markers, cardiac infarction markers, autoimmune, etc., and plans to import high quality antigen or antibody from companies in other countries in order to research and develop new agents. It is envisaged that the government will vigorously promote the development of the community health care system and this will result in the majority of community hospitals needing quick detection products. This company aims to be the leader in introducing innovative POCT (Point-of-care Testing) detection agents or systems to better serve the domestic testing market.

Expected countries (regions) for cooperation:

Scientific research institute or enterprise in European countries and USA

If you can meet this technoloyg need please contact us quoting: REF/1479/Antigens or antibodies for in vitro diagnostic reagents; Innovative POCT detection kits or system

Back